Ricevi le ultime notizie sulle azioni Camp4 Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CAMP

Ultime notizie per

Camp4 Therapeutics

Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

CalAmp

Healthcare Workers Sound the Alarm

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

CAMP

EWTX

GNFT

Dopo il recente ribasso, queste 3 azioni sanitarie ipervendute potrebbero sorprenderti con un forte rimbalzo nel Q2.

Affari d&#39;oro nella sanità? 3 azioni ipervendute pronte al rimbalzo

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics Corp

CalAmp Corp

Camping World Holdings, Inc. Class A Common Stock

Camping World Holdings Inc

Campbell International Holding Corp

CAMPBELL RES INC by Campbell Resources Inc.

Campbell Resources Inc

Press Releases

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Management

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Earnings

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

Health Care

General

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

Sequans Appoints Jason W. Cohenour to Board of Directors

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

LTRX

RFIL

SQNS

SWIR

TSX:BLN

TSX:SW

Adicet Bio

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

aTyr Pharma

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Equillium

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

Immix Biopharma

INmune Bio

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

MAIA Biotechnology

Medicus Pharma

MediciNova

OS Therapies

Plus Therapeutics

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Cantor Fitzgerald

Piper Sandler

Wedbush

Leerink Partners

JP Morgan

Comments

Camp4 Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO